查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830288

Castleman氏病治疗市场（按治疗类型、治疗线、分销管道和最终用户划分）—2025-2032 年全球预测

Castleman Disease Treatment Market by Treatment Type, Line Of Therapy, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年， Castleman氏病治疗市场规模将成长至 9.5452 亿美元，复合年增长率为 14.01%。

主要市场统计数据
基准年2024年 3.3415亿美元
预计2025年 3.8066亿美元
预测年份：2032年 9.5452亿美元
复合年增长率（%） 14.01%

对Castleman氏病的临床复杂性以及影响治疗决策的不断发展的治疗和护理框架的策略概述

Castleman氏病带来了复杂的临床和商业挑战，涵盖免疫学、肿瘤学和罕见疾病管理。患者表现出多种疾病表现，从可局部治疗的单中心疾病到需要多学科治疗的多中心全身性疾病。延迟诊断和异质性临床表现增加了未满足的医疗需求，而细胞激素讯号传导作用的持续演变也显着改变了临床治疗重点。

过去十年，治疗策略已从经验性地广泛使用免疫抑制和细胞毒性疗法，转变为生物目标干预，从而改变了许多患者的病程。随着药物学创新的推进，医疗服务模式也不断发展，涵盖居家治疗、跨学科临床合作以及旨在提高患者生活品质和依从性的综合患者支持机制。由于相关人员关注临床影响和操作可行性，治疗领域需要製定能够协调科学进步与可近性、报销和实际应用等现实情况的策略。

重塑Castleman氏病治疗的最重大转变源自于生物目标、生物标记主导策略和新型治疗模式

近期机制和治疗方法的进展改变了研究、临床和患者支持模式。对白细胞介素-6通路和细胞激素调控的密切关注，已将研究投入转向生物製药和单株抗体，而生物标记发现方面的同步努力旨在对患者进行分层，以便进行更有针对性的干预，并识别出最有可能获得持久获益的患者。这种科学关注正在引发一系列下游变革，影响研究设计、对照药物选择和监管交互作用。

同时，医疗服务交付领域的创新正在加速。居家管理、远端医疗追踪和综合专科诊所网路的兴起重塑了病患的参与度和依从性。伴随这些变化的是支付方和医疗服务提供者的调整，强调基于价值的合约和基于结果的证据。总而言之，这些转变要求相关人员重新评估临床路径、供应链韧性和商业策略，以更好地关注目标有效性、以患者为中心的交付方式以及可衡量的现实世界结果。

2025 年美国关税政策的变化将如何影响Castleman氏病药物供应链、筹资策略和取得的连续性

2025年美国关税调整为参与治疗罕见免疫介导疾病的製造商、经销商和医疗保健提供者带来了新的考量。即使核心生物製药本身是在特殊贸易条款下生产的，活性药物原料药、一次性器械、包装组件和低温运输物流等辅助投入也容易受到跨境成本转移的影响。进口关税和物流额外费用的变化迫使相关人员重新评估采购决策和库存策略，以维持对弱势患者群体的持续照护。

在实践中，这些供应侧的成本压力可能促使製造商考虑近岸外包、寻找合格的替代供应商或加强垂直整合，以控制价值链中的关键节点。医疗系统和专科药房的应对措施是缩短采购週期并增强缓衝能力，以降低治疗中断的风险。从商业性角度来看，定价、合约和病患援助计画的谈判必须考虑到土地征用成本上升和潜在延误等营运现实。从策略角度来看，积极规划关税风险并建立灵活采购模式的机构能够在保持药品供应的同时，有效管理利润率，并确保患者坚持治疗。

深入的细分洞察，解释治疗类型、治疗线、分销管道和医疗保健环境如何影响临床和商业执行

清晰地了解患者群组和治疗途径对于解读治疗反应和规划商业性方案至关重要。治疗细分区分了化疗方案和生物目标，其中化疗进一步透过联合治疗与单药疗法进行分析，皮质类固醇的使用则透过地塞米松和泼尼松等药物进行区分。这种细分有助于了解广谱免疫抑制疗法与精准标靶治疗的临床前景，并支持临床医生决策中至关重要的安全性和耐受性比较考量。

治疗线细分反映了介入措施在一线、第二线和后线治疗中的定位，其中一线治疗方案进一步细分为联合治疗和单药治疗策略。区分线下和线上通路可以揭示患者获取途径、配药工作流程和依从性支持方面的差异。终端使用者分析可以明确护理的提供地点，例如居家照护、医院和专科诊所，并将居家照护进一步细分为自我管理和上门护理服务，以反映患者独立性、培训需求和监测强度方面的差异。这种细分提供了多方面的视角，有助于制定有针对性的临床方案、优化供应链规划并客製化服务。

美洲、欧洲、中东和非洲以及亚太地区的区域差异如何定义访问路径、采用模式和商业性方法？

区域动态对临床应用、报销策略和可近性途径有着巨大的影响。在美洲，专科中心和成熟的转诊网络推动了靶向生技药品的应用，并支持了稳健的临床试验活动。虽然这种区域生态系统有助于快速将证据推广到实践中，但不同医疗机构和人群在药物可及性方面仍有差异。

欧洲、中东和非洲地区（EMEA）是一个多元化的地区，其监管环境、报销标准和医疗保健体系结构差异巨大。在一些西欧市场，集中式专家网路和健康技术评估流程促进了实证应用。同时，亚太市场将生物製药生产能力的快速扩张与成本敏感的支付方环境结合。虽然各国的趋势各不相同，但它们正在推动多样化的商业性模式，从本地製造伙伴关係到分级定价和旨在改善可及性和病患监测的数位参与模式。

公司正在采用商业和发展策略来区分治疗方法、扩大获取途径并建立永续的证据生成项目

Castleman氏病的关键商业和开发策略着重于整个价值链的创新，而非单一的差异化点。本公司优先考虑透过标靶作用机制获得持续的临床效益，透过研究者主导临床实验和註册性试验拓宽适应症范围，并在生命週期临床实验与产品组合多元化之间取得平衡，以降低单一产品风险。与製造商、临床研究机构和专业药房建立策略伙伴关係关係是扩大复杂生物製药生产规模和简化患者获取途径的常用策略。

除了研发管线和生产方面的考虑，成功的公司还在病患支援计画、真实世界证据产生和临床医生教育方面进行投资，以加速产品的应用并向付款人展示其价值。定价策略越来越多地体现了领先标价与基于疗效的合约和风险分担模式相结合的模式。同时，生物相似药和替代生物製药竞争对手的进入潜力凸显了透过卓越的安全性、便捷的给药方式以及在真实世界中可验证的长期疗效来实现差异化的重要性。

为行业领导者提供实用的优先建议，以协调临床创新、获取策略和营运弹性，实现长期成功

行业领导者应优先考虑一系列整合的、可操作的倡议，将临床有效性与可及性和营运韧性相结合。首先，对诊断准确性和生物标记项目的投资将使患者选择更加精准，并加强付款人对话，从而减少比较有效性的不确定性。其次，实现製造和供应伙伴关係的多元化，包括区域产能和可行的替代供应商，将减少因关税导致的成本转移和物流中断的风险。

第三，建立强大的病患支援基础设施，包括家庭管理培训、到府护理师服务和数位依从性工具，可以提高现实世界病患的依从性和临床疗效。第四，儘早与付款方合作，设计基于疗效或基于价值的合约安排，有助于填补证据空白，扩大覆盖范围，同时协调奖励。最后，公司应采用证据连续体方法，将随机数据与现实世界的註册数据和患者报告的疗效相结合，以支持其长期定位和生命週期策略。

透过结合临床文献、相关人员访谈和真实世界数据三角测量的严格混合方法研究途径获得可靠的见解

本文的研究结果源自于混合方法研究途径，旨在平衡临床严谨性和现实世界的适用性。此调查方法整合了对同行评审文献和临床试验註册库的全面回顾，以及对执业临床医生、专业药剂师和付款人代表进行的定性访谈，以了解实践模式和报销驱动因素。我们分析了现实世界资料来源和观察性註册库证据，以检验治疗途径，并描述对照试验以外的依从性和安全性概况。

为确保稳健性，我们采用了数据三角测量和交叉验证，并透过反覆专家咨询来解释模糊或不一致的讯号。关键变量，例如治疗方式、治疗线、治疗场所和分销管道，均采用统一编码，以便跨资料流进行比较分析。在整个研究过程中，我们严格遵守伦理和资料管治标准，并整合研究结果，以根据当前临床实践和营运现状提供切实可行的见解。

将治疗创新转化为Castleman氏病持续临床和营运影响的证据和策略方向的简明综合

总而言之，生物目标的进展和不断发展的治疗模式正在重塑Castleman氏病的治疗格局，为相关人员带来机会和义务。儘管围绕细胞激素调节的科学进步已为许多患者带来了有意义的改善，但与药物可及性、供应链韧性和多变的报销环境相关的结构性挑战仍然存在。应对这些挑战需要在临床、商业和营运领域采取协调一致的行动，以确保治疗成果转化为持续的患者获益。

展望未来，整合生物标记指导的患者选择、灵活的筹资策略、以付款​​人为中心的价值展示以及以患者为中心的交付模式的组织将最有能力将创新转化为现实影响。涵盖研发、上市和核准后证据产生的整体策略，为改善Castleman氏病病患者的预后，同时维持商业性可行性和营运永续性，提供了最清晰的途径。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 临床实验Situximab生物相似药的临床试验进展扩大了多中心Castleman氏病的治疗选择
  • 精准医疗方法利用生物标记物来客製化Castleman氏病的治疗方法，从而提高其采用率
  • 加大对以JAK-STAT讯号为标靶的小分子抑制剂在难治性Castleman氏病治疗中的投入
  • 学术机构与生物製药公司加强合作，加速Castleman氏病新型疗法的开发
  • 下一代抗 IL-6 受体药物的监管核准改变了 Castleman 症候群患者的治疗前景。
  • 加强病患就医计画和报销策略，以减轻治疗罕见疾病的经济负担

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章Castleman氏病治疗市场（依治疗类型）

  • 化疗
    • 联合治疗
    • 单一疗法
  • 皮质类固醇
    • 地塞米松
    • 强的松
  • Situximab
  • 托珠单抗

第九章Castleman氏病治疗市场治疗线

  • 第一行
    • 联合治疗
    • 单一疗法
  • 后面几行
  • 第二行

第 10 章Castleman氏病治疗市场（依通路）

  • 离线
  • 在线的

第 11 章Castleman氏病治疗市场：依最终使用者划分

  • 居家照护环境
    • 自我管理
    • 到府护理服务
  • 医院
  • 专科诊所

第十二章Castleman氏病治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章Castleman氏病治疗市场：依类别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章Castleman氏病治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Janssen Biotech, Inc.
    • Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • EUSA Pharma（UK）Limited
    • Swedish Orphan Biovitrum AB
    • Grifols, SA
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Bristol-Myers Squibb Company
Product Code: MRR-4312A385A340

The Castleman Disease Treatment Market is projected to grow by USD 954.52 million at a CAGR of 14.01% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 334.15 million
Estimated Year [2025] USD 380.66 million
Forecast Year [2032] USD 954.52 million
CAGR (%) 14.01%

A strategic overview of Castleman disease clinical complexity and the evolving therapeutic and care delivery frameworks shaping treatment decisions

Castleman disease presents a complex clinical and operational challenge that spans immunology, oncology, and rare disease management. Patients experience a spectrum of presentations from unicentric forms amenable to localized intervention to multicentric and systemic variants that demand sustained multidisciplinary care. Diagnostic delays and heterogeneity in clinical presentation intensify unmet needs, while advances in understanding the central role of cytokine signaling have reframed therapeutic priorities across clinical practice.

Over the past decade, therapeutic pathways have moved from empiric use of broad immunosuppression and cytotoxic approaches toward targeted biologic interventions that alter disease trajectory for many patients. Alongside pharmacologic innovation, care delivery models have evolved to encompass home-based regimens, specialty clinic coordination, and integrated patient support mechanisms that address quality of life and adherence. For stakeholders focused on clinical impact and operational feasibility, the treatment landscape requires strategies that reconcile scientific progress with access, reimbursement, and real-world implementation realities.

The most significant shifts reshaping Castleman disease care arising from targeted biologics, biomarker-driven strategies, and novel care delivery models

Recent mechanistic and therapeutic advances have catalyzed transformative shifts across research, clinical practice, and patient support paradigms. A sharper focus on the interleukin-6 pathway and cytokine modulation has redirected research investments to biologics and monoclonal antibodies, while parallel efforts in biomarker discovery aim to stratify patients for more precise interventions and to identify those most likely to derive durable benefit. This scientific pivot is producing a cascade of downstream changes that affect trial design, comparator selection, and regulatory dialogue.

Concurrently, delivery innovation has accelerated. The rise of home administration, telemedicine-enabled follow-up, and integrated specialty clinic networks has reshaped patient touchpoints and adherence frameworks. These changes are accompanied by payer and provider adaptations that emphasize value-based contracting and outcomes-based evidence. Taken together, these shifts require stakeholders to re-evaluate clinical pathways, supply chain resilience, and commercial strategies to align with a landscape that prizes targeted efficacy, patient-centric delivery, and measurable real-world outcomes.

How changes in United States tariff policy in 2025 are influencing supply chains, sourcing strategies, and continuity of access for Castleman disease therapeutics

Tariff adjustments enacted in the United States during 2025 have introduced new considerations for manufacturers, distributors, and care providers involved in treating rare immune-mediated conditions. Even when core biologic agents themselves may be produced under specialized trade terms, ancillary inputs such as active pharmaceutical ingredients, single-use devices, packaging components, and cold-chain logistics are sensitive to cross-border cost shifts. As import duties and logistical surcharges change, stakeholders must reassess sourcing decisions and inventory strategies to preserve continuity of care for vulnerable patient cohorts.

In practice, these supply-side cost pressures can prompt manufacturers to explore nearshoring, alternative supplier qualification, or increased vertical integration to control critical nodes of the value chain. Health systems and specialty pharmacies respond by refining procurement cycles and expanding buffering capabilities to reduce the risk of treatment interruption. From a commercial perspective, negotiations around pricing, contracting, and patient assistance programs will need to incorporate the operational realities of higher landed costs and potential delays. Strategically, organizations that proactively map tariff exposures and build flexible sourcing models will be positioned to maintain access while managing margin implications and preserving treatment adherence for patients.

Deep segmentation insights explaining how treatment types, lines of therapy, distribution channels, and care settings shape clinical and commercial execution

A clear understanding of patient cohorts and therapeutic pathways is essential when interpreting treatment responses and planning commercial approaches. Treatment segmentation distinguishes between chemotherapy approaches and targeted biologics, with chemotherapy further analyzed across combination therapy and monotherapy modalities, and corticosteroid use delineated by agents such as dexamethasone and prednisone. This granularity clarifies where clinical practice favors broad immunosuppression compared to precision targeting, and it informs comparative safety and tolerability discussions that are central to clinician decision-making.

Line-of-therapy segmentation captures how interventions are positioned across first line, second line, and later-line settings, with first-line approaches further differentiated by combination therapy versus monotherapy strategies. Distribution channel distinctions between offline and online pathways reveal differences in patient access, dispensing workflows, and adherence supports. End-user analysis underscores where care is delivered-home care settings, hospitals, or specialty clinics-with further subdivision of home care into self-administration and visiting nurse services to reflect variations in patient independence, training needs, and monitoring intensity. Together, these segmentations enable a multidimensional view of the landscape that supports targeted clinical programs, optimized supply chain planning, and tailored patient services.

How regional differences across the Americas, Europe Middle East & Africa, and Asia-Pacific define access pathways, adoption patterns, and commercial approaches

Regional dynamics exert a powerful influence on clinical adoption, reimbursement strategy, and access pathways. In the Americas, specialized centers and established referral networks accelerate adoption of targeted biologics and support robust clinical trial activity, while payer frameworks and patient assistance programs shape out-of-pocket exposure and formulary positioning. This regional ecosystem tends to favor rapid dissemination of evidence into practice, although disparities in access persist across different care settings and population groups.

The Europe, Middle East & Africa region presents a heterogenous landscape where regulatory processes, reimbursement criteria, and health system structures vary widely. In several Western European markets, centralized expert networks and health technology assessment processes promote evidence-based adoption, whereas other markets within the region experience slower uptake due to resource constraints and distribution barriers. Meanwhile, Asia-Pacific markets combine rapid capacity expansion in biologic manufacturing with cost-sensitive payer environments; variations across countries drive diverse commercial approaches, ranging from local manufacturing partnerships to tiered pricing and digital engagement models aimed at improving access and patient monitoring.

Commercial and development strategies that companies are adopting to differentiate therapies, expand access, and build sustainable evidence generation programs

Leading commercial and development strategies in the Castleman disease space emphasize innovation across the value chain rather than a single point of differentiation. Companies are prioritizing durable clinical benefit through targeted mechanisms of action, expanding indication breadth through investigator-sponsored and registrational studies, and balancing lifecycle management with portfolio diversification to mitigate single-product risk. Strategic partnerships with manufacturing, clinical research organizations, and specialty pharmacies are common tactics to scale complex biologic production and to streamline patient access pathways.

Beyond pipeline and manufacturing considerations, successful organizations invest in patient support programs, real-world evidence generation, and clinician education to accelerate uptake and demonstrate value to payers. Pricing strategies increasingly reflect a blend of upfront list prices supplemented by outcomes-based agreements or risk-sharing models. At the same time, the potential entrance of biosimilar or alternative biologic competitors underscores the importance of differentiation through superior safety profiles, simplified administration, or demonstrable long-term outcomes in real-world settings.

Practical and prioritized recommendations for industry leaders to align clinical innovation, access strategies, and operational resilience for long-term success

Industry leaders should prioritize a set of integrated, actionable moves that align clinical efficacy with access and operational resilience. First, investment in diagnostic precision and biomarker programs will enable more accurate patient selection and stronger payer conversations, reducing uncertainty about comparative effectiveness. Second, diversifying manufacturing and supply partnerships, including regional production capacities and validated alternative suppliers, will mitigate exposure to tariff-driven cost shifts and logistical disruption.

Third, building robust patient support infrastructure that spans home administration training, visiting nurse services, and digital adherence tools will enhance real-world persistence and clinical outcomes. Fourth, engaging payers early to design outcomes-based or value-based contracting arrangements can bridge evidence gaps and unlock coverage while aligning incentives. Finally, companies should adopt an evidence continuum approach that combines randomized data with real-world registries and patient-reported outcomes to support long-term positioning and lifecycle strategy.

A rigorous mixed-methods research approach combining clinical literature, stakeholder interviews, and real-world data triangulation to ensure robust insights

The findings presented here derive from a mixed-methods research approach designed to balance clinical rigor with real-world applicability. The methodology integrates a comprehensive review of peer-reviewed literature and clinical trial registries with qualitative interviews conducted with treating clinicians, specialty pharmacists, and payer representatives to capture practice patterns and reimbursement drivers. Real-world data sources and observational registry evidence were analyzed to validate treatment pathways and to contextualize adherence and safety profiles outside controlled trials.

Data triangulation and cross-validation were employed to ensure robustness, with iterative expert consultations used to interpret ambiguous or inconsistent signals. Key variables such as treatment modality, line of therapy, care setting, and distribution channel were coded consistently to allow comparative analysis across data streams. Throughout the research process, ethical and data governance standards were observed, and findings were synthesized to provide actionable insights that remain grounded in current clinical practice and operational realities.

A concise synthesis of evidence and strategic direction to convert therapeutic innovation into sustained clinical and operational impact for Castleman disease

In conclusion, advances in targeted biologic therapies and evolving care delivery models are reshaping the Castleman disease treatment landscape in ways that create both opportunity and obligation for stakeholders. Scientific progress around cytokine modulation has delivered meaningful improvements for many patients, but structural challenges related to access, supply chain resilience, and variable reimbursement environments remain. Addressing these challenges requires coordinated action across clinical, commercial, and operational domains to ensure that therapeutic gains translate into sustained patient benefit.

Looking ahead, organizations that integrate biomarker-driven patient selection, resilient sourcing strategies, payer-aligned value demonstration, and patient-centric delivery models will be best positioned to convert innovation into real-world impact. A holistic strategy that spans development, market access, and post-approval evidence generation offers the clearest pathway to improving outcomes for patients living with Castleman disease while maintaining commercial viability and operational sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical trial advancements in investigational siltuximab biosimilars expanding treatment options for multicentric Castleman disease
  • 5.2. Growing adoption of precision medicine approaches leveraging biomarkers to tailor Castleman disease therapy regimens
  • 5.3. Rising investment in small molecule inhibitors targeting JAK-STAT signaling for refractory Castleman disease management
  • 5.4. Increasing collaboration between academic centers and biopharma firms accelerating novel Castleman disease drug development
  • 5.5. Regulatory approvals of next generation anti-IL-6 receptor agents transforming treatment landscape for Castleman patients
  • 5.6. Enhanced patient access programs and reimbursement strategies improving affordability of rare disease therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Castleman Disease Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Combination Therapy
    • 8.1.2. Monotherapy
  • 8.2. Corticosteroids
    • 8.2.1. Dexamethasone
    • 8.2.2. Prednisone
  • 8.3. Siltuximab
  • 8.4. Tocilizumab

9. Castleman Disease Treatment Market, by Line Of Therapy

  • 9.1. First Line
    • 9.1.1. Combination Therapy
    • 9.1.2. Monotherapy
  • 9.2. Later Lines
  • 9.3. Second Line

10. Castleman Disease Treatment Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Castleman Disease Treatment Market, by End User

  • 11.1. Home Care Settings
    • 11.1.1. Self Administration
    • 11.1.2. Visiting Nurse Services
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Castleman Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Castleman Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Castleman Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Janssen Biotech, Inc.
    • 15.3.2. Hoffmann-La Roche Ltd
    • 15.3.3. Pfizer Inc.
    • 15.3.4. EUSA Pharma (UK) Limited
    • 15.3.5. Swedish Orphan Biovitrum AB
    • 15.3.6. Grifols, S.A.
    • 15.3.7. AbbVie Inc.
    • 15.3.8. Takeda Pharmaceutical Company Limited
    • 15.3.9. Novartis AG
    • 15.3.10. Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY H